niacin has been researched along with Infection in 19 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pellagra is a curable dietary illness that unchecked leads to dementia, diarrhoea, dermatitis and death due to lack of the precursors for NAD(H)." | 3.74 | Pellagra: A clue as to why energy failure causes diseases? ( Ramsden, DB; Williams, AC, 2007) |
| " However, the trial also identified previously unrecognized serious adverse effects (including new-onset diabetes, bleeding, and infection)." | 2.90 | Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. ( Armitage, J; Chen, F; Haynes, R; Hopewell, JC; Landray, MJ; Li, J; Parish, S; Valdes-Marquez, E, 2019) |
| "Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3." | 2.79 | Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014) |
| "Local infections are often unusually severe." | 1.29 | Pellagra--increased viscosity of extracellular matrix. ( Stone, OJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haynes, R | 3 |
| Valdes-Marquez, E | 1 |
| Hopewell, JC | 2 |
| Chen, F | 1 |
| Li, J | 1 |
| Parish, S | 2 |
| Landray, MJ | 3 |
| Armitage, J | 3 |
| Lloyd-Jones, DM | 1 |
| Aung, T | 1 |
| Tomson, J | 1 |
| Wallendszus, K | 1 |
| Craig, M | 1 |
| Jiang, L | 1 |
| Collins, R | 1 |
| McCarthy, M | 1 |
| Huynh, K | 1 |
| Rembold, CM | 1 |
| Meneses, F | 1 |
| Hu, M | 1 |
| Tomlinson, B | 1 |
| van den Oever, IA | 1 |
| Nurmohamed, MT | 1 |
| Lems, WF | 1 |
| Santos-Gallego, CG | 1 |
| Badimon, J | 1 |
| Mayer, L | 1 |
| Bloomfield, HE | 1 |
| CAYER, D | 1 |
| CODY, S | 1 |
| LEVENSON, SM | 1 |
| GREEN, RW | 1 |
| NORMAND, J | 1 |
| Williams, AC | 1 |
| Ramsden, DB | 1 |
| Stone, OJ | 1 |
| Gopalan, C | 1 |
| Srikantia, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630] | Phase 3 | 25,673 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 807 |
| Placebo | 897 |
Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 668 |
| Placebo | 694 |
Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 1696 |
| Placebo | 1758 |
All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 798 |
| Placebo | 732 |
Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 498 |
| Placebo | 499 |
1 review available for niacin and Infection
| Article | Year |
|---|---|
Nutrition and disease.
Topics: Adult; Anemia, Hypochromic; Anemia, Macrocytic; Antibody Formation; Blood Bactericidal Activity; Chi | 1973 |
2 trials available for niacin and Infection
| Article | Year |
|---|---|
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug T | 2019 |
Effects of extended-release niacin with laropiprant in high-risk patients.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin | 2014 |
16 other studies available for niacin and Infection
| Article | Year |
|---|---|
Niacin and HDL cholesterol--time to face facts.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin fails to reduce vascular events in large randomised trial.
Topics: Blood Glucose; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combi | 2014 |
Dyslipidaemia: Niacin-laropiprant fails to reduce the risk of vascular events.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Niacin for reduction of cardiovascular risk.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
ACP Journal Club: adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events.
Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma | 2014 |
Urinary excretion of niacin and riboflavin in patients with acute infections and various chronic diseases.
Topics: Acute Disease; Chronic Disease; Humans; Infections; Niacin; Nicotinic Acids; Riboflavin; Urine | 1948 |
Ascorbic acid, riboflavin, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human.
Topics: Ascorbic Acid; Deficiency Diseases; Hemorrhage; Humans; Infections; Metabolism; Niacin; Nicotinic Ac | 1946 |
[MEDICO-SURGICAL TREATMENT OF OBLITERATING ARTERIOPATHIES OF THE LOWER EXTREMITIES WITHOUT ACUTE ISCHEMIA. THE POINT OF VIEW OF THE PHYSICIAN].
Topics: Anticoagulants; Arteriosclerosis Obliterans; Autonomic Nerve Block; Embolism; Hypertonic Solutions; | 1964 |
Pellagra: A clue as to why energy failure causes diseases?
Topics: Animals; Biochemistry; Diet; Humans; Infections; Inflammation; Metabolism; Models, Biological; Model | 2007 |
Pellagra--increased viscosity of extracellular matrix.
Topics: Central Nervous System; Digestive System; Extracellular Matrix; Female; Glycosaminoglycans; Humans; | 1993 |